COVID-19 Pandemic-Related Changes in Rates of Neonatal Abstinence Syndrome

Sarka Lisonkova; Jeffrey N Bone; Qi Wen; Giulia M Muraca; Joseph Y Ting; Neda Razaz; K S Joseph

doi:10.1001/jamanetworkopen.2024.1651

COVID-19 Pandemic-Related Changes in Rates of Neonatal Abstinence Syndrome

JAMA Netw Open. 2024 Mar 4;7(3):e241651. doi: 10.1001/jamanetworkopen.2024.1651.

Authors

Sarka Lisonkova^{1

2}, Jeffrey N Bone^{1

3}, Qi Wen¹, Giulia M Muraca^{4

5}, Joseph Y Ting⁶, Neda Razaz⁷, K S Joseph^{1

2}

Affiliations

¹ Department of Obstetrics and Gynaecology, University of British Columbia and the Children's and Women's Hospital and Health Centre of British Columbia, Vancouver, British Columbia, Canada.
² School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.
³ Division of Biostatistics, British Columbia Children's Hospital Research Institute, Vancouver, British Columbia, Canada.
⁴ Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.
⁵ Department of Obstetrics and Gynecology, McMaster University, Hamilton, Ontario, Canada.
⁶ Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada.
⁷ Clinical Epidemiology Division, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.

No abstract available

Plain language summary

This cross-sectional study examines COVID-19 pandemic–related changes in rates of neonatal abstinence syndrome (NAS) and whether infants in urban or rural areas and those with low socioeconomic status were disproportionately affected.

MeSH terms

Analgesics, Opioid / therapeutic use
COVID-19*
Humans
Infant, Newborn
Neonatal Abstinence Syndrome* / drug therapy
Neonatal Abstinence Syndrome* / epidemiology
Opioid-Related Disorders* / epidemiology
Pandemics

Substances

Analgesics, Opioid